Choi Yoori, Ha Seunggyun, Lee Yun-Sang, Kim Yun Kyung, Lee Dong Soo, Kim Dong Jin
1Department of Nuclear Medicine, College of Medicine, Seoul National University, 110-744, 28 Yongon-Dong, Jongno-Gu, Seoul, South Korea.
2Department of Nuclear Medicine, Seoul National University Hospital, 28 Yongon-Dong, Jongno-Gu, Seoul, 110-744 South Korea.
Nucl Med Mol Imaging. 2018 Feb;52(1):24-30. doi: 10.1007/s13139-017-0484-7. Epub 2017 Jun 7.
The pathological features of Alzheimer's disease are senile plaques which are aggregates of β-amyloid peptides and neurofibrillary tangles in the brain. Neurofibrillary tangles are aggregates of hyperphosphorylated tau proteins, and these induce various other neurodegenerative diseases, such as progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobar degeneration, frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and chronic traumatic encephalopathy. In the case of Alzheimer's disease, the measurement of neurofibrillary tangles associated with cognitive decline is suitable for differential diagnosis, disease progression assessment, and to monitor the effects of therapeutic treatment. This review discusses considerations for the development of tau ligands for imaging and summarizes the results of the first-in-human and preclinical studies of the tau tracers that have been developed thus far. The development of tau ligands for imaging studies will be helpful for differential diagnosis and for the development of therapeutic treatments for tauopathies including Alzheimer's disease.
阿尔茨海默病的病理特征是脑内存在由β-淀粉样肽聚集形成的老年斑和神经原纤维缠结。神经原纤维缠结是过度磷酸化的tau蛋白的聚集体，这些聚集体还会引发其他各种神经退行性疾病，如进行性核上性麻痹、皮质基底节变性、额颞叶变性、额颞叶痴呆以及与17号染色体相关的帕金森病（FTDP-17）和慢性创伤性脑病。对于阿尔茨海默病而言，测量与认知衰退相关的神经原纤维缠结适用于鉴别诊断、疾病进展评估以及监测治疗效果。本综述讨论了用于成像的tau配体开发的相关考量，并总结了迄今为止已开发出的tau示踪剂的首例人体研究和临床前研究结果。用于成像研究的tau配体的开发将有助于鉴别诊断以及开发针对包括阿尔茨海默病在内的tau蛋白病的治疗方法。
